VIPoma other imaging findings
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma other imaging findings On the Web |
|
American Roentgen Ray Society Images of VIPoma other imaging findings |
|
Risk calculators and risk factors for VIPoma other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3]
Overview
Other imaging studies for VIPoma include somatostatin receptor scintigraphy and PET scan using radiolabeled somatostatin analogs.
Other Imaging Findings
Somatostatin receptor scintigraphy (Octreoscan) is used to localise the tumor, which is usually metastatic at presentation. Nearly 80-90% of all VIPoma are somatostatin receptor positive.[1]
-
![PET-CT with MBq 68-Gallium-DOTATOC showing enhancement of multiple lesions in the right lobe of the liver (upper image) and a slight enhancement in the caudal pancreas (lower image).[2]](/images/f/f3/PET_CT.jpg)
PET-CT with MBq 68-Gallium-DOTATOC showing enhancement of multiple lesions in the right lobe of the liver (upper image) and a slight enhancement in the caudal pancreas (lower image).[2]
![PET-CT with MBq 68-Gallium-DOTATOC showing enhancement of multiple lesions in the right lobe of the liver (upper image) and a slight enhancement in the caudal pancreas (lower image).[2]](/index.php/File:PET_CT.jpg)
References
- ↑ Abu-Zaid A, Azzam A, Abudan Z, Algouhi A, Almana H, Amin T (2014). "Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male". Hematol Oncol Stem Cell Ther. 7 (3): 109–15. doi:10.1016/j.hemonc.2014.03.002. PMID 24785507.
- ↑ Müller, Sven; Kupka, Susan; Königsrainer, Ingmar; Northoff, Hinnak; Sotlar, Karl; Bock, Thomas; Kandolf, Reinhard; Traub, Frank; Königsrainer, Alfred; Zieker, Derek (2012). "MSH2 and CXCR4 involvement in malignant VIPoma". World Journal of Surgical Oncology. 10 (1): 264. doi:10.1186/1477-7819-10-264. ISSN 1477-7819.